International Leukemia Target Board for children with relapsed hematologic malignancies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The International Leukemia Target Board (iLTB) is a collaborative initiative aimed at prioritizing treatment options for children with relapsed or refractory hematological malignancies. This observational project brings together a multidisciplinary team of experts to analyze molecular and immunophenotypic data, as well as drug response profiles, to guide treatment decisions. The iLTB will monitor the implementation of its recommendations and track patient outcomes, providing valuable insights into the effectiveness of various treatment strategies. By harmonizing approaches across Europe, the iLTB seeks to improve the management of complex cases in pediatric oncology.

Why it matters

Who can join: the full rules

Inclusion criteria

1. The patient has been diagnosed with a R/R hematological malignancy;
2. The patient is less than 18 years of age at the time of first diagnosis and less than 25 years at the time of inclusion with relapse/refractory hematological malignancy;
3. The patient is treated in a pediatric/AYA setting or study protocol, with no current standard of care treatment;
4. The patients' life expectancy is at least 6 weeks;
5. The patient has undergone any sort of molecular profiling of his/her tumor and the re-sults of this analysis are available;
6. The patient has undergone flow cytometry in a certified lab and results are available;
7. Written informed consent of patient and/or parent(s)/guardian(s) to discuss the patient in the iLTB according to local law and legislation has been obtained.

Exclusion criteria: none defined

Where it's running

• UH Gent
  Ghent, Belgium Recruiting
• Righospitalet
  Copenhagen, Denmark Recruiting
• Semmelweis
  Budapest, Hungary Recruiting
• Princess Máxima Center for Pediatric Oncology
  Utrecht, Utrecht, Netherlands Recruiting
• Vall d'Hebron
  Barcelona, Spain Recruiting
• Queen Silvia
  Gothenburg, Sweden Recruiting

Study contacts

• Principal investigator: Michel Zwaan, Prof. dr. — Princess Maxima Center for Pediatric Oncology
• Study coordinator: Uri Ilan, MD
• Email: iltb@prinsesmaximacentrum.nl
• Phone: +31889725206

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term follow-up for patients who received genetically modified cell therapy

  This study is tracking the long-term health effects of gene therapy in patients with blood cancers to see how they are doing 15 years after treatment.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT05713214

• Evaluating Emavusertib for Relapsed or Refractory Primary Central Nervous System Lymphoma

  This study is testing a new drug called emavusertib, alone and with another medication, to see if it can help adults with tough-to-treat primary central nervous system lymphoma feel better.

  Recruiting at 35 sites Phase 1/2 Curis, Inc. · Phoenix, Arizona and 44 other locations · NCT03328078

• Evaluating HDM2005 for patients with relapsed B-cell lymphoma and advanced solid tumors

  This study is testing a new drug called HDM2005 to see if it can help people with relapsed B-cell lymphoma and advanced solid tumors feel better.

  Recruiting at 4 sites Phase 1 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Zhengzhou, Henan and 7 other locations · NCT06615193

• Digital health coaching for adults with relapsed multiple myeloma

  This study is testing a digital health coaching program for adults with relapsed multiple myeloma to see if it can help improve their quality of life and health management.

  Recruiting Pack Health · Seattle, Washington · NCT05956457

• Mobile app to help cancer patients with advance care planning

  This study tests whether a mobile app can help cancer patients talk about and plan their future care wishes with their families and doctors better than standard care alone.

  Recruiting Fred Hutchinson Cancer Center · Manhasset, New York and 3 other locations · NCT04515810

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.